ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis
Journal of Dermatological Treatment
◽
10.1080/09546634.2016.1214671
◽
2016
◽
Vol 28
(1)
◽
pp. 3-7
◽
Cited By ~ 5
Author(s):
Huaming Tan
◽
Hernan Valdez
◽
Chris E.M. Griffiths
◽
Ulrich Mrowietz
◽
Anna Tallman
◽
...
Keyword(s):
Clinical Response
◽
Plaque Psoriasis
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Download Full-text
Related Documents
Cited By
References
Early clinical response as a predictor of subsequent response to tofacitinib treatment: Results from two phase 3 studies of subjects with moderate to severe plaque psoriasis
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2016.02.956
◽
2016
◽
Vol 74
(5)
◽
pp. AB244
Keyword(s):
Clinical Response
◽
Plaque Psoriasis
◽
Treatment Results
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
◽
Subsequent Response
Download Full-text
Correction to: Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis
Journal of Dermatological Treatment
◽
10.1080/09546634.2016.1245484
◽
2017
◽
Vol 28
(1)
◽
pp. x-x
Keyword(s):
Clinical Response
◽
Plaque Psoriasis
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Download Full-text
Impact of previous biologic use and failure on efficacy of brodalumab and ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials in moderate-to-severe plaque psoriasis (AMAGINE-2 and AMAGINE-3)
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2017.06.065
◽
2017
◽
Vol 76
(6)
◽
pp. AB405
Keyword(s):
Clinical Trials
◽
Plaque Psoriasis
◽
Randomized Clinical Trials
◽
Pooled Analysis
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Download Full-text
Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.4.supp.80
◽
2020
◽
Vol 4
(6)
◽
pp. s80
Author(s):
A Blauvelt
◽
RB Warren
◽
K Reich
◽
F Brock
◽
F Fierens
◽
...
Keyword(s):
Plaque Psoriasis
◽
Certolizumab Pegol
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Abstract not available.
Download Full-text
Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.5.supp.19
◽
2021
◽
Vol 5
(1)
◽
pp. s19
Author(s):
A Blauvelt
◽
RB Warren
◽
K Reich
◽
F Brock
◽
F Fierens
◽
...
Keyword(s):
Plaque Psoriasis
◽
Certolizumab Pegol
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Abstract not available.
Download Full-text
Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
SKIN The Journal of Cutaneous Medicine
◽
10.25251/skin.3.supp.29
◽
2019
◽
Vol 3
◽
pp. S29
Author(s):
Mark G Lebwohl
◽
Jeffrey L Sugarman
◽
Linda Stein Gold
◽
Tina Lin
◽
Gina Martin
Keyword(s):
Randomized Controlled Trials
◽
Plaque Psoriasis
◽
Fixed Combination
◽
Controlled Trials
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
◽
Post Hoc Analysis
◽
Randomized Controlled
◽
Post Hoc
Abstract not available.
Download Full-text
Impact of brodalumab on work productivity in patients with moderate-to-severe plaque psoriasis: Analysis of two phase 3 studies
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2018.05.649
◽
2018
◽
Vol 79
(3)
◽
pp. AB158
Keyword(s):
Plaque Psoriasis
◽
Work Productivity
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Download Full-text
Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2017.04.648
◽
2017
◽
Vol 76
(6)
◽
pp. AB167
Keyword(s):
Clinical Trials
◽
Treatment Response
◽
Median Time
◽
Plaque Psoriasis
◽
Randomized Clinical Trials
◽
Pooled Analysis
◽
Phase 3
◽
Two Phase
◽
Time To Treatment
◽
Severe Plaque Psoriasis
Download Full-text
Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: Integrated analysis of two phase 3 trials
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2019.06.211
◽
2019
◽
Vol 81
(4)
◽
pp. AB49
Keyword(s):
Plaque Psoriasis
◽
Integrated Analysis
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Download Full-text
Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2015.02.275
◽
2015
◽
Vol 72
(5)
◽
pp. AB66
Keyword(s):
Plaque Psoriasis
◽
Efficacy And Safety
◽
Phase 3
◽
Two Phase
◽
Severe Plaque Psoriasis
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close